BioWorld

July 10, 2008

Portola Raises $60M in Series C Extension

Portola Pharmaceuticals Inc. raised $60 million in a Series C extension round to drive its two lead cardiovascular product candidates through Phase II clinical trials. (BioWorld Today) Read More

Study Shows Pipex's Zinc-Based Drug Improved Dry AMD

Drugs, Vaccines, Surveillance for Influenza All Get Boosts

SGX Shares Soar on Merger Giving Lilly Technology Boost

FDA Axing Approvable Letters, Adding Complete Responses

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 22, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 22, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...